{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:30:29Z","timestamp":1791822629692,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002878","name":"Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n, Ciencia y Empleo de la Junta de Andaluc\u00eda","doi-asserted-by":"crossref","award":["CTS-7748"],"award-info":[{"award-number":["CTS-7748"]}],"id":[{"id":"10.13039\/501100002878","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Salud Mental-CIBERSAM","award":["CB\/07\/09\/0033"],"award-info":[{"award-number":["CB\/07\/09\/0033"]}]},{"name":"\u201cMinisterio de Econom\u00eda y Competitividad\u201d (MINECO), co-financed by \u201cFondo Europeo de Desarrollo Regional\u201d FEDER \u201cA way to build Europe\u201d","award":["\u201cInstituto de Salud Carlos III (PI12\/00915)"],"award-info":[{"award-number":["\u201cInstituto de Salud Carlos III (PI12\/00915)"]}]},{"name":"Fundaci\u00f3n Progreso y Salud de la Junta de Andaluc\u00eda","award":["PI-0080-2017"],"award-info":[{"award-number":["PI-0080-2017"]}]},{"name":"2015 NARSAD Young Investigator Grant from the Brain Behavior Research Foundation","award":["NARSAD 23982"],"award-info":[{"award-number":["NARSAD 23982"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Tissue Res"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00441-018-2978-8","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T21:00:48Z","timestamp":1547067648000},"page":"107-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Monoaminergic system and depression"],"prefix":"10.1007","volume":"377","author":[{"given":"L.","family":"Perez-Caballero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Torres-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Romero-L\u00f3pez-Alberca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gonz\u00e1lez-Saiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Mico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Berrocoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,10]]},"reference":[{"key":"2978_CR1","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1176\/appi.ajp.158.10.1617","volume":"158","author":"LL Altshuler","year":"2001","unstructured":"Altshuler LL, Bauer M, Frye MA, Gitlin MJ, Mintz J, Szuba MP, Leight KL, Whybrow PC (2001) Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry 158:1617\u20131622","journal-title":"Am J Psychiatry"},{"key":"2978_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric Publishing, Arlington"},{"key":"2978_CR3","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1001\/archpsyc.1996.01830090090013","volume":"53","author":"R Aronson","year":"1996","unstructured":"Aronson R, Offman HJ, Joffe RT, Naylor CD (1996) Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry 53:842\u2013848","journal-title":"Arch Gen Psychiatry"},{"key":"2978_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/S0166-2236(96)10037-0","volume":"19","author":"F Artigas","year":"1996","unstructured":"Artigas F, Romero L, de Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378\u2013383","journal-title":"Trends Neurosci"},{"key":"2978_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.euroneuro.2017.10.032","volume":"28","author":"F Artigas","year":"2018","unstructured":"Artigas F, Bortolozzi A, Celada P (2018) Can we increase speed and efficacy of antidepressant treatments? Part I: general aspects and monoamine-based strategies. Eur Neuropsychopharmacol 28:445\u2013456","journal-title":"Eur Neuropsychopharmacol"},{"key":"2978_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0165-0327(02)00404-4","volume":"79","author":"J Ballesteros","year":"2004","unstructured":"Ballesteros J, Callado LF (2004) Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 79:137\u2013147","journal-title":"J Affect Disord"},{"key":"2978_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40263-014-0152-8","volume":"28","author":"M Bauer","year":"2014","unstructured":"Bauer M, Adli M, Ricken R, Severus E, Pilhatsch M (2014) Role of lithium augmentation in the management of major depressive disorder. CNS Drugs 28:331\u2013342","journal-title":"CNS Drugs"},{"key":"2978_CR8","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.2174\/138161209788168100","volume":"15","author":"E Berrocoso","year":"2009","unstructured":"Berrocoso E, Sanchez-Blazquez P, Garzon J, Mico JA (2009) Opiates as antidepressants. Curr Pharm Des 15:1612\u20131622","journal-title":"Curr Pharm Des"},{"key":"2978_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0165-6147(94)90315-8","volume":"15","author":"P Blier","year":"1994","unstructured":"Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220\u2013226","journal-title":"Trends Pharmacol Sci"},{"key":"2978_CR10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.neuropharm.2005.11.020","volume":"50","author":"LJ Boothman","year":"2006","unstructured":"Boothman LJ, Mitchell SN, Sharp T (2006) Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis. Neuropharmacology 50:726\u2013732","journal-title":"Neuropharmacology"},{"key":"2978_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000357500","volume":"83","author":"AF Carvalho","year":"2014","unstructured":"Carvalho AF, Berk M, Hyphantis TN, McIntyre RS (2014) The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 83:70\u201388","journal-title":"Psychother Psychosom"},{"key":"2978_CR12","first-page":"252","volume":"29","author":"P Celada","year":"2004","unstructured":"Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29:252\u2013265","journal-title":"J Psychiatry Neurosci"},{"key":"2978_CR13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/S0140-6736(67)91894-6","volume":"2","author":"A Coppen","year":"1967","unstructured":"Coppen A, Shaw DM, Herzberg B, Maggs R (1967) Tryptophan in the treatment of depression. Lancet 2:1178\u20131180","journal-title":"Lancet"},{"key":"2978_CR14","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nrd3140","volume":"9","author":"C Bodinat de","year":"2010","unstructured":"de Bodinat C, Guardiola-Lemaitre B, Mocaer E, Renard P, Munoz C, Millan MJ (2010) Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 9:628\u2013642","journal-title":"Nat Rev Drug Discov"},{"key":"2978_CR15","first-page":"450","volume":"120","author":"R Domenjoz","year":"1959","unstructured":"Domenjoz R, Theobald W (1959) On the pharmacology of tofranil N-(3-dimethylaminopropyl)-iminodibenzyl hydrochloride. Arch Int Pharmacodyn Ther 120:450\u2013489","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2978_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001547","volume":"10","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, Vos T, Whiteford HA (2013a) Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 10:e1001547","journal-title":"PLoS Med"},{"key":"2978_CR17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1017\/S0033291712001511","volume":"43","author":"AJ Ferrari","year":"2013","unstructured":"Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, Whiteford HA (2013b) Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 43:471\u2013481","journal-title":"Psychol Med"},{"key":"2978_CR18","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"GBD Disease and Injury Incidence and Prevalence Collaborators","year":"2016","unstructured":"GBD Disease and Injury Incidence and Prevalence Collaborators (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545\u20131602","journal-title":"Lancet"},{"key":"2978_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1586\/14737175.2013.811901","volume":"13","author":"C Han","year":"2013","unstructured":"Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU (2013) Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 13:851\u2013870","journal-title":"Expert Rev Neurother"},{"key":"2978_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1176\/ps.2009.60.11.1466","volume":"60","author":"TR Insel","year":"2009","unstructured":"Insel TR, Wang PS (2009) The STAR*D trial: revealing the need for better treatments. Psychiatr Serv 60:1466\u20131467","journal-title":"Psychiatr Serv"},{"key":"2978_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nature07455","volume":"455","author":"V Krishnan","year":"2008","unstructured":"Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455:894\u2013902","journal-title":"Nature"},{"key":"2978_CR22","first-page":"1135","volume":"87","author":"R Kuhn","year":"1957","unstructured":"Kuhn R (1957) Treatment of depressive states with an iminodibenzyl derivative (G 22355). Schweiz Med Wochenschr 87:1135\u20131140","journal-title":"Schweiz Med Wochenschr"},{"key":"2978_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0269881114553252","volume":"29","author":"RM Lane","year":"2015","unstructured":"Lane RM (2015) Antidepressant drug development: focus on triple monoamine reuptake inhibition. J Psychopharmacol 29:526\u2013544","journal-title":"J Psychopharmacol"},{"key":"2978_CR24","first-page":"522","volume":"74","author":"G Lemieux","year":"1956","unstructured":"Lemieux G, Davignon A, Genest J (1956) Depressive states during Rauwolfia therapy for arterial hypertension; a report of 30 cases. Can Med Assoc J 74:522\u2013526","journal-title":"Can Med Assoc J"},{"key":"2978_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/138945006775515482","volume":"7","author":"T Lifschytz","year":"2006","unstructured":"Lifschytz T, Segman R, Shalom G, Lerer B, Gur E, Golzer T, Newman ME (2006) Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 7:203\u2013210","journal-title":"Curr Drug Targets"},{"key":"2978_CR26","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1038\/s41598-018-21243-x","volume":"8","author":"GY Lim","year":"2018","unstructured":"Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC (2018) Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep 8:2861","journal-title":"Sci Rep"},{"key":"2978_CR27","first-page":"129","volume":"8","author":"HP Loomer","year":"1957","unstructured":"Loomer HP, Saunders JC, Kline NS (1957) A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc 8:129\u2013141","journal-title":"Psychiatr Res Rep Am Psychiatr Assoc"},{"key":"2978_CR28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2174\/138161209788168001","volume":"15","author":"F Lopez-Munoz","year":"2009","unstructured":"Lopez-Munoz F, Alamo C (2009) Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 15:1563\u20131586","journal-title":"Curr Pharm Des"},{"key":"2978_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/JCP.0000000000000723","volume":"37","author":"RS McIntyre","year":"2017","unstructured":"McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, Kennedy SH, Rong C, Jerrell JM (2017) The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis. J Clin Psychopharmacol 37:412\u2013418","journal-title":"J Clin Psychopharmacol"},{"key":"2978_CR30","doi-asserted-by":"crossref","unstructured":"Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-Sanchez E, Gutierrez-Rojas L, Meana JJ (2018) Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs","DOI":"10.1007\/s40263-018-0519-3"},{"key":"2978_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/NDT.S91311","volume":"12","author":"A Montoya","year":"2016","unstructured":"Montoya A, Bruins R, Katzman MA, Blier P (2016) The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 12:541\u2013557","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl 1","key":"2978_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2165\/1159616-S0-000000000-00000","volume":"31","author":"R Moreira","year":"2011","unstructured":"Moreira R (2011) The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 31(Suppl 1):5\u201317","journal-title":"Clin Drug Investig"},{"key":"2978_CR33","volume-title":"Depression: management of depression in primary and secondary care (National Clinical Practice Guideline No 23)","author":"National Institute for Clinical Excellence","year":"2004","unstructured":"National Institute for Clinical Excellence (2004) Depression: management of depression in primary and secondary care (National Clinical Practice Guideline No 23). NICE, London"},{"key":"2978_CR34","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","volume":"166","author":"JC Nelson","year":"2009","unstructured":"Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980\u2013991","journal-title":"Am J Psychiatry"},{"key":"2978_CR35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1176\/ajp.2006.163.9.1519","volume":"163","author":"AA Nierenberg","year":"2006","unstructured":"Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ (2006) A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 163:1519\u20131530","journal-title":"Am J Psychiatry"},{"key":"2978_CR36","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0140-6736(96)08007-5","volume":"349","author":"V Perez","year":"1997","unstructured":"Perez V, Gilaberte I, Faries D, Alvarez E, Artigas F (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594\u20131597","journal-title":"Lancet"},{"key":"2978_CR37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/mp.2013.63","volume":"19","author":"L Perez-Caballero","year":"2014","unstructured":"Perez-Caballero L, Perez-Egea R, Romero-Grimaldi C, Puigdemont D, Molet J, Caso JR, Mico JA, Perez V, Leza JC, Berrocoso E (2014) Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs. Mol Psychiatry 19:607\u2013614","journal-title":"Mol Psychiatry"},{"key":"2978_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4088\/JCP.v66n0201","volume":"66","author":"MA Posternak","year":"2005","unstructured":"Posternak MA, Zimmerman M (2005) Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 66:148\u2013158","journal-title":"J Clin Psychiatry"},{"key":"2978_CR39","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905\u20131917","journal-title":"Am J Psychiatry"},{"key":"2978_CR40","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/17460441.2016.1160051","volume":"11","author":"ZT Sahli","year":"2016","unstructured":"Sahli ZT, Banerjee P, Tarazi FI (2016) The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert Opin Drug Discovery 11:515\u2013523","journal-title":"Expert Opin Drug Discovery"},{"key":"2978_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","volume":"145","author":"C Sanchez","year":"2015","unstructured":"Sanchez C, Asin KE, Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 145:43\u201357","journal-title":"Pharmacol Ther"},{"key":"2978_CR42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1176\/ajp.122.5.509","volume":"122","author":"JJ Schildkraut","year":"1965","unstructured":"Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122:509\u2013522","journal-title":"Am J Psychiatry"},{"key":"2978_CR43","first-page":"181","volume":"515","author":"K Smith","year":"2014","unstructured":"Smith K (2014) Mental health: a world of depression. Nature 515:181","journal-title":"Nature"},{"key":"2978_CR44","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1192\/bjp.178.3.234","volume":"178","author":"ME Thase","year":"2001","unstructured":"Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178:234\u2013241","journal-title":"Br J Psychiatry"},{"key":"2978_CR45","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/YIC.0b013e328330adb2","volume":"25","author":"ME Thase","year":"2010","unstructured":"Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH (2010) Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 25:189\u2013198","journal-title":"Int Clin Psychopharmacol"},{"key":"2978_CR46","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa052964","volume":"354","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ, Team SDS (2006) Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243\u20131252","journal-title":"N Engl J Med"},{"key":"2978_CR47","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0140-6736(03)12705-5","volume":"361","author":"UK ECT Review Group","year":"2003","unstructured":"UK ECT Review Group (2003) Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361:799\u2013808","journal-title":"Lancet"},{"key":"2978_CR48","doi-asserted-by":"crossref","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM, Rodriguez CI, Schatzberg AF (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry:appiajp201818020138","DOI":"10.1176\/appi.ajp.2018.18020138"},{"key":"2978_CR49","doi-asserted-by":"crossref","unstructured":"Won E, Kim YK (2017) An oldie but goodie: lithium in the treatment of bipolar disorder through neuroprotective and neurotrophic mechanisms. Int J Mol Sci 18","DOI":"10.3390\/ijms18122679"},{"key":"2978_CR50","volume-title":"The world health report 2001: mental health: now understanding, new hope","author":"World Health Organization","year":"2001","unstructured":"World Health Organization (2001) The world health report 2001: mental health: now understanding, new hope. World Health Organization, Geneva"},{"key":"2978_CR51","volume-title":"Out of the shadows: making mental health a global development priority","author":"World Health Organization","year":"2016","unstructured":"World Health Organization (2016) Out of the shadows: making mental health a global development priority. World Health Organization, Washington"},{"key":"2978_CR52","volume-title":"Depression and other common mental disorders: global health estimates","author":"World Health Organization","year":"2017","unstructured":"World Health Organization (2017) Depression and other common mental disorders: global health estimates. World Health Organization, Geneva"}],"container-title":["Cell and Tissue Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-018-2978-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00441-018-2978-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00441-018-2978-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T19:07:23Z","timestamp":1578596843000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00441-018-2978-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,10]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["2978"],"URL":"https:\/\/doi.org\/10.1007\/s00441-018-2978-8","relation":{},"ISSN":["0302-766X","1432-0878"],"issn-type":[{"value":"0302-766X","type":"print"},{"value":"1432-0878","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,10]]},"assertion":[{"value":"19 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}